ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia
(pamidronate disodium for injection) for the treatment of patients
with osteolytic bone metastases of breast cancer, in conjunction
with standard antineoplastic therapy.
The drug has been on the market since 1991 and is also indicated
for the treatment of osteolytic bone lesions of multiple myeloma,
moderate-to-severe hypercalcemia of malignancy, and moderate-to-severe